9 recruiting, 7 unknown, 2 completed, 1 active not recruiting. 19 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Recruiting 9, Unknown 7, Completed 2, Active not recruiting 1 |
| Phase 1 | 12 | Recruiting 6, Unknown 4, Completed 2 |
Follow Toripalimab Injection: new trials by email Literature Review of Toripalimab Injection trials Research Report on Toripalimab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors IPG7236, Toripalimab Injection - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Nanjing Immunophage Biotech Co., Ltd | 52 | 2026-06-16 | 2026-06-29 |
| A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer LBL-024 for Injection, albumin-bound Paclitaxel injection, Toripalimab Injection - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 220 | 2026-01-27 | 2026-02-12 |
| A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. LBL-024 for Injection, Toripalimab Injection - Advanced Melanoma | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2025-09-05 | 2026-10-21 |
| 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer 9MW2821, Toripalimab Injection - Urothelial Carcinoma | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 90 | 2025-08-01 | 2026-01-02 |
| A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, Paclitaxel injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Lyvgen Biopharma Holdings Limited | 64 | 2024-06-21 | 2026-05-19 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-03-01 | 2024-03-12 |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Risen (Suzhou) Pharma Tech Co., Ltd. | 306 | 2024-01-11 | 2025-07-25 |
| 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer 9MW2821, Toripalimab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 100 | 2023-09-27 | 2024-09-19 |
| A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors RC118, Toripalimab, RC148 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | RemeGen Co., Ltd. | 48 | 2023-08-03 | 2025-01-29 |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors MSC-IFNα, Nab paclitaxel, Cyclophosphamide - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 40 | 2023-02-23 | 2023-04-28 |
| Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer CT-707, Toripalimab, Gemcitabine - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Shouyao Holdings (Beijing) Co. LTD | 114 | 2022-08-11 | 2023-11-22 |
| A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors LBL-007 Injection, Toripalimab Injection - Advanced Malignant Tumors | Phase 1 / Phase 2 | Completed | Nanjing Leads Biolabs Co.,Ltd | 80 | 2021-11-30 | 2025-06-03 |
| PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Toripalimab Injection - Stomach Neoplasms | Phase 2 | Recruiting | Wan He | 62 | 2021-09-14 | 2025-02-05 |
| Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment stage, Adjuvant treatment stage - NSCLC Stage IV, Oligometastasis | Phase 2 | Unknown | Tang-Du Hospital | 30 | 2021-08-31 | 2021-09-24 |
| A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC X4P-001 - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Abbisko Therapeutics Co, Ltd | 24 | 2021-07-21 | 2021-11-02 |
| Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma Toripalimab, Bevacizumab, Nab-paclitaxel - Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer | Phase 2 | Unknown | Sichuan Cancer Hospital and Research Institute | 27 | 2021-04-06 | 2021-04-06 |
| A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer Toripalimab Injection, Cetuximab Solution for infusion - Head and Neck Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 88 | 2021-04-06 | 2026-08-04 |
| Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy Toripalimab Injection - NSCLC Stage IV | Phase 2 | Unknown | Fujian Cancer Hospital | 30 | 2020-12-01 | 2020-11-03 |
| Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma Donafenib Tosilate Tablets, Toripalimab Injection - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 46 | 2020-10-15 | 2022-11-29 |
Carcinoma, Non-Small-Cell Lung (3) · Triple Negative Breast Neoplasms (2) · Carcinoma, Transitional Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Lung Diseases (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Thoracic Neoplasms (1)
Nanjing Leads Biolabs Co.,Ltd (3) · Mabwell (Shanghai) Bioscience Co., Ltd. (2) · Abbisko Therapeutics Co, Ltd (1) · Chinese PLA General Hospital (1) · Fujian Cancer Hospital (1) · Lyvgen Biopharma Holdings Limited (1) · Nanjing Immunophage Biotech Co., Ltd (1) · RemeGen Co., Ltd. (1) · Risen (Suzhou) Pharma Tech Co., Ltd. (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Shouyao Holdings (Beijing) Co. LTD (1) · Sichuan Cancer Hospital and Research Institute (1) · Sun Yat-sen University (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Tang-Du Hospital (1)
China (19)
J L Zheng, Director (1) · Juan Li, MD (1) · Keli Zhong, PhD (1) · Mian Xi, MD (1) · Shukui Qin, PhD (1) · Tao Jiang, PH.D (1) · Tianshu Liu, ph.D (1) · Wan He, PhD (1) · WeiDong Han, PhD (1) · Ye Guo (1) · Ye Guo, Doctor (1) · Yinghui Sun, PhD (1) · Yu Chen (1) · Yufang Shi, PhD (1) · Zhiyong He, master (1)
PMID 34351356, PMID 35419831, PMID 36990609, PMID 37195667, PMID 42260304